Detalhe da pesquisa
1.
Quality of life with cemiplimab plus chemotherapy for first-line treatment of advanced non-small cell lung cancer: Patient-reported outcomes from phase 3 EMPOWER-Lung 3.
Cancer
; 129(14): 2256-2265, 2023 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37151113
2.
Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial.
Lancet Oncol
; 23(4): 465-478, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35298906
3.
Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer: The ASTRUM-005 Randomized Clinical Trial.
JAMA
; 328(12): 1223-1232, 2022 09 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-36166026
4.
Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.
Lancet Oncol
; 22(4): 450-462, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33794205
5.
Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.
Lancet Oncol
; 22(1): 51-65, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33285097
6.
Trifluridine/tipiracil in patients with metastatic gastroesophageal junction cancer: a subgroup analysis from the phase 3 TAGS study.
Gastric Cancer
; 24(4): 970-977, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33713215
7.
Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.
Lancet
; 394(10212): 1929-1939, 2019 11 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-31590988
8.
Health-related quality of life associated with trifluridine/tipiracil in heavily pretreated metastatic gastric cancer: results from TAGS.
Gastric Cancer
; 23(4): 689-698, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32128634
9.
Maintenance avelumab versus continuation of first-line chemotherapy in gastric cancer: JAVELIN Gastric 100 study design.
Future Oncol
; 15(6): 567-577, 2019 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-30379568
10.
Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol
; 19(11): 1437-1448, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30355453
11.
Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial.
Lancet
; 388(10063): 2997-3005, 2016 12 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-27908454
12.
De Novo Sequencing of Peptides from Top-Down Tandem Mass Spectra.
J Proteome Res
; 14(11): 4450-62, 2015 Nov 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-26412692
13.
De novo protein sequencing by combining top-down and bottom-up tandem mass spectra.
J Proteome Res
; 13(7): 3241-8, 2014 Jul 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-24874765
14.
Comparison of Efficacy and Safety of a Bevacizumab Biosimilar, in Combination with Chemotherapies, in Nonresectable Metastatic Colorectal Cancer and in Advanced Nonsquamous Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Phase III Study.
South Asian J Cancer
; 13(1): 66-76, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-38721097
15.
Efficacy and safety of maintenance therapy with pamiparib versus placebo for advanced gastric cancer responding to first-line platinum-based chemotherapy: Phase 2 study results.
Cancer Med
; 12(12): 13145-13154, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37260158
16.
Tislelizumab Versus Docetaxel in Patients With Previously Treated Advanced NSCLC (RATIONALE-303): A Phase 3, Open-Label, Randomized Controlled Trial.
J Thorac Oncol
; 18(1): 93-105, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36184068
17.
Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial.
Nat Med
; 28(11): 2374-2380, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36008722
18.
Randomized phase 3 study of the anti-disialoganglioside antibody dinutuximab and irinotecan vs irinotecan or topotecan for second-line treatment of small cell lung cancer.
Lung Cancer
; 166: 135-142, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35278766
19.
New Therapies and Biomarkers: Are We Ready for Personalized Treatment in Small Cell Lung Cancer?
Am Soc Clin Oncol Educ Book
; 41: 1-10, 2021 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-33979194
20.
Efficacy and Safety of Bevacizumab Biosimilar FKB238 Versus Originator Bevacizumab: Results from AVANA, a Phase III Trial in Patients with Non-Squamous Non-Small-Cell Lung Cancer (non-sq-NSCLC).
BioDrugs
; 35(4): 417-428, 2021 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-34264503